Author

Barbara Burroni

InsermORCID 0009-0008-7816-1900Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Research Focus:benchmarking· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Assay:DNA methylation· 1 Research Focus:drug response / drug discovery· 1 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

Adélaïde Ferment· 1 shared Alice MachadoiD· 1 shared Anaïs LevescotiD· 1 shared Antoine de Giacomoni· 1 shared Audrey Mansuet‐LupoiD· 1 shared Aurélie Thomas· 1 shared Benoît TerrisiD· 1 shared Berta MarzaliD· 1 shared

Activity by Year

2026-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Adélaïde Ferment

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

ImmunologybioRxivPreprintJul 28, 2026

Safety profiling of CAR-T cells using an organotypic human tissue platform

Alice Machado, Gary Birsen, Irena Rajnpreht…·Emmanuel Donnadieu

This paper develops an organotypic human tissue platform to assess CAR-T cell toxicity and shows it can predict tissue-specific toxicity profiles and identify factors influencing off-tumor effects.

DOI 10.64898/2026.07.25.740527

humanexperimental assay

𝕏 PostBluesky

Cancer BiologyGastroenterologyPeer-reviewedApr 17, 2026

CLONAL LYMPHOCYTE EXPANSIONS AND JAK-STAT PATHWAY MUTATIONS DEFINE A PATHOGENIC CONTINUUM DRIVING RESISTANCE TO GLUTEN-FREE DIET IN CELIAC DISEASE

Georgia Malamut, Nicolas Guégan, Francesco Carbone…·Anaïs Levescot

This study identifies clonal lymphocyte expansions and JAK-STAT mutations in celiac disease subtypes, revealing shared mechanisms and limitations of JAK inhibitor therapy.

3 citationstop 1%

humanscRNA-seq

𝕏 PostBluesky